MSD applies for ‘Zepatier’ approval, expecting competition among hepatitis C therapies

Published: 2016-07-27 13:03:10

Updated: 2016-07-27 13:03:10

Another oral hepatitis C treatment seems to be introduced in Korea.

According to the industry concerned on the 26^th, MSD turned in approval application of a new oral direct acting antiviral, ‘Zepatier(elbasvir+grazoprevir).’ It is expected to be approved within this year.

The drug is a complex in a new combination of a protease inhibitor, grazoprevir, such as ‘Victrelis(boceprevir),’ with N...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.